I. Summary

Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, as set forth in this document, is a final administrative order (final order) as deemed by sections 505G(b)(8) and 505G(k)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355h(b)(8) and 355h(k)(2)(B)), effective upon enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law 116-136, on March 27, 2020.

II. Background

The CARES Act added section 505G of the FD&C Act, which revised the framework for the regulation of over-the-counter (OTC) monograph drug products. Among other things, section 505G provides as a baseline status that, as of the date of enactment of the CARES Act, a sunscreen drug that satisfies certain requirements is deemed to be generally recognized as safe and effective (GRASE) and not a new drug.1 To obtain this status, among other requirements, a sunscreen drug must be in conformity with

the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations.2

The statute established these as “the applicable requirements in terms of conformity with a final monograph” for these sunscreen drugs.3

Complementary to these requirements for conformity to the specified final monograph, section 505G also deemed certain items to be final administrative orders under section 505G(b). In the case of sunscreens, these encompass not only the requirements of pre-CARES Act monograph rulemaking documents described by 505G(a)(2), but also certain “[r]egulations in effect on the day before the date of the enactment of [section 505G], establishing requirements for specific

---

1 Section 505G(a)(1)(A)(i) and 505G(a)(2) of the FD&C Act; but see section 505G(m)(2), discussed further in this section II and footnote 7.
2 Section 505G(a)(2) of the FD&C Act.
3 Id.
nonprescription drugs marketed pursuant to [section 505G]]. Thus, the final order for OTC sunscreen drug products incorporates the final monograph requirements, as specified by 505G(a)(2), from 21 CFR part 352 (as published on May 21, 1999) and from 21 CFR 201.327 (as in effect on March 26, 2020, the day prior to the date of enactment of section 505G).

Under section 505G(b)(8)(C) of the FD&C Act, the deemed establishment of a final order is construed to include technical amendments necessary to ensure that the order is appropriately harmonized, in terms of terminology or cross-references, with the applicable provisions of the FD&C Act (and regulations) and any other final orders issued under section 505G of the FD&C Act. This final order for OTC sunscreen drug products includes technical amendments to facilitate the combination of 21 CFR part 352 and 21 CFR 201.327 into one order, including updates to headings, numbering, and cross-references, and to use the current established names for active ingredients. Provisions of the order that incorporate an ISO standard by reference continue to incorporate the same version as the preceding regulation, but no longer cite 5 U.S.C. 552 and 1 CFR part 51 in light of the transition from regulations to orders and include updated information on how to access the material. The order also contains a number of corrections to typographical errors and erroneous cross-references that appeared in the published regulations.

This final order may be amended, revoked, or otherwise modified in accordance with the procedures described in section 505G of the FD&C Act.

Under section 505G(a)(1) of the FD&C Act, sunscreens that conform to the requirements for nonprescription use embodied in this final order (and to the other requirements specified by section 505G of the FD&C Act, including the general requirements for nonprescription drugs) are deemed to be GRASE and not new drugs. However “notwithstanding subsection [505G](a),” by operation of section 505G(m)(2) of the FD&C Act, sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder currently require an application approved under section 505 of the FD&C Act in order to be marketed. Sunscreens in

---

4 See sections 505G(b)(8) and 505G(k)(2) of the FD&C Act.
5 See also section 3854(c)(1) of the CARES Act (establishing requirement to “amend and revise the final administrative order concerning nonprescription sunscreen (referred to in this subsection as the ‘sunscreen order’))” and further describing that order by referring to a 1999 version of 21 CFR part 352.)
6 In this OTC Monograph, each active ingredient is identified by its current established name, as defined in section 502(e)(3) of the FD&C Act (21 U.S.C.352(e)(3)), by which it is required to be identified in labeling. In some cases, this differs from the name by which the active ingredient was identified in 21 CFR part 352, as published on May 21, 1999. Section M020.10 presents these ingredients in alphabetical order using the current names. For convenience, where a name has changed, the name used in the 1999 publication is provided in an associated footnote.
7 Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6024 at 6229-6230 (Feb. 26, 2019); see also 84 FR at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&C Act.
dosage forms that cannot currently be legally marketed without an approved application (or a final order issued under 505G) include sunscreen wipes, towelettes, body washes, and shampoos.

III. Final Administrative Order

Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use

Part A—General Provisions

Sec.
M020.1 Scope

Part B—Active Ingredients

M020.10 Sunscreen active ingredients
M020.20 Permitted combinations of active ingredients

Part C—Labeling

§ M020.50 Labeling of sunscreen drug products

Part D—Testing Procedures

§ M020.80 Sun Protection Factor (SPF) test procedure
§ M020.90 Broad spectrum test procedure

Part A—General Provisions

§ M020.1 Scope

An over-the-counter (OTC) sunscreen drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this OTC monograph and each general condition established in 21 CFR 330.1.

Part B—Active Ingredients

§ M020.10 Sunscreen active ingredients

The active ingredient of the product consists of any of the following, within the concentration specified for each ingredient, and the finished product provides a minimum sun protection factor (SPF) value of not less than 2 as measured by the testing procedures established in § M020.80:

(a) Aminobenzoic acid (PABA) up to 15 percent.

(b) Avobenzone up to 3 percent.
(c) Cinoxate up to 3 percent.
(d) Dioxybenzone up to 3 percent.
(e) Ensulizole\(^8\) up to 4 percent.
(f) Homosalate up to 15 percent.
(g) Meradimate\(^9\) up to 5 percent.
(h) Octinoxate\(^10\) up to 7.5 percent.
(i) Octisalate\(^11\) up to 5 percent.
(j) Octocrylene up to 10 percent.
(k) Oxybenzone up to 6 percent.
(l) Padimate O up to 8 percent.
(m) Sulisobenzone up to 10 percent.
(n) Titanium dioxide up to 25 percent.
(o) Trolamine salicylate up to 12 percent.
(p) Zinc oxide up to 25 percent.

§ M020.20 Permitted combinations of active ingredients

The SPF of any combination product is measured by the testing procedures established in § M020.80.

(a) Combinations of sunscreen active ingredients.

---

\(^8\) Previously identified as Phenylbenzimidazole sulfonic acid.
\(^9\) Previously identified as Menthyl anthranilate.
\(^10\) Previously identified as Octyl methoxycinnamate.
\(^11\) Previously identified as Octyl salicylate.
(1) Two or more sunscreen active ingredients identified in §§ M020.10(a), (c), (d), (e), (f), and (g) through (p) may be combined with each other in a single product when used in the concentrations established for each ingredient in § M020.10. The concentration of each active ingredient must be sufficient to contribute a minimum SPF of not less than 2 to the finished product. The finished product must have a minimum SPF of not less than the number of sunscreen active ingredients used in the combination multiplied by 2.

(2) Two or more sunscreen active ingredients identified in §§ M020.10(b), (c), (d), (f), (h) through (k), (m), and (o) may be combined with each other in a single product when used in the concentrations established for each ingredient in § M020.10. The concentration of each active ingredient must be sufficient to contribute a minimum SPF of not less than 2 to the finished product. The finished product must have a minimum SPF of not less than the number of sunscreen active ingredients used in the combination multiplied by 2.

Part C—Labeling

§ M020.50 Labeling of sunscreen drug products

(a) Principal display panel. In addition to the statement of identity in § M020.50(b), the following labeling shall be prominently placed on the principal display panel:

(1) Effectiveness claim

(i) For products that pass the broad spectrum test in § M020.90.

(A) The labeling states "Broad Spectrum SPF [insert numerical SPF value resulting from testing under § M020.80]".

(B) Prominence. The Broad Spectrum SPF statement shall appear as continuous text with no intervening text or graphic. The entire text shall appear in the same font style, size, and color with the same background color.

(ii) For sunscreen products that do not pass the broad spectrum test in § M020.90. The labeling states "SPF [insert numerical SPF value resulting from testing under § M020.80]". The entire text shall appear in the same font style, size, and color with the same background color.

(2) Water resistance statements

(i) For products that provide 40 minutes of water resistance according to the test in § M020.80(g)(1). The labeling states "Water Resistant (40 minutes)".

(ii) For products that provide 80 minutes of water resistance according to the test in § M020.80(g)(2). The labeling states "Water Resistant (80 minutes)".
(b) Statement of identity. The labeling of the product contains the established name of the drug, if any, and identifies the drug as a "sunscreen."

(c) Indications. The labeling of the product states, under the heading "Uses," the phrases listed in § M020.50(c), as appropriate. Other truthful and nonmisleading statements, describing only the uses that have been established and listed in § M020.50(c), may also be used, as provided in 21 CFR 330.1(c)(2), subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 352) relating to misbranding and the prohibition in section 301(d) of the FD&C Act (21 U.S.C. 331(d)) against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the FD&C Act (21 U.S.C. 355(a)).

(1) For all sunscreen products, the following indication statement must be included under the heading "Uses": 

[Bullet] helps prevent sunburn.

(2) For sunscreen products with a Broad Spectrum SPF value of 15 or higher according to the tests in §§ M020.80 and M020.90, the labeling may include the following statement in addition to the indication in § M020.50(c)(1):

[Bullet] if used as directed with other sun protection measures (see Directions [in bold italic font]), decreases the risk of skin cancer and early skin aging caused by the sun.

(3) Any labeling or promotional materials that suggest or imply that the use, alone, of any sunscreen reduces the risk of or prevents skin cancer or early skin aging will cause the product to be misbranded under section 502 of the FD&C Act.

(d) Warnings. The labeling of the product contains the following warnings under the heading "Warnings".

(1) For all sunscreen products.

(i) The labeling states "Do not use [bullet] on damaged or broken skin".

(ii) The labeling states "When using this product [bullet] keep out of eyes. Rinse with water to remove."

(iii) The labeling states "Stop use and ask a doctor if [bullet] rash occurs".

(2) For sunscreen products that are broad spectrum with SPF values of at least 2 but less than 15 according to the SPF test in §M020.80 or that do not pass the broad spectrum test in § M020.90. The first statement under the heading "Warnings" states "Skin Cancer/Skin Aging Alert [in bold font]: Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to help prevent sunburn, not [in bold font] skin cancer or early skin aging."

12 See 21 CFR 201.66(b)(4).
(e) Directions. The labeling of the product contains the following statements, as appropriate, under the heading "Directions." More detailed directions applicable to a particular product formulation may also be included.

(1) For all sunscreen products.

(i) As an option, the labeling may state "For sunscreen use:"

(ii) The labeling states "[bullet] apply [select one of the following: 'Liberally' or 'generously'] [and, as an option: 'And evenly'] 15 minutes before sun exposure".

(iii) As an option, the labeling may state "[bullet] apply to all skin exposed to the sun".

(iv) The labeling states "[bullet] children under 6 months of age: Ask a doctor".

(2) For sunscreen products with a Broad Spectrum SPF value of 15 or higher according to the tests in §§ M020.80 and M020.90. The labeling states "[bullet] Sun Protection Measures. [in bold font] Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: [Bullet] limit time in the sun, especially from 10 a.m.-2 p.m. [bullet] wear long-sleeved shirts, pants, hats, and sunglasses".

(3) For products that satisfy the water resistance test in § M020.80(g). The labeling states "[bullet] reapply: [Bullet] after [select one of the following determined by water resistance test: '40 minutes of' or '80 minutes of'] swimming or sweating [bullet] immediately after towel drying [bullet] at least every 2 hours".

(4) For products that do not satisfy the water resistance test in § M020.80(g). The labeling states "[bullet] reapply at least every 2 hours [bullet] use a water resistant sunscreen if swimming or sweating".

(f) Other information. The labeling of the product contains the following statement under the heading "Other information:" "[bullet] protect the product in this container from excessive heat and direct sun".

(g) False and misleading claims. There are claims that would be false and/or misleading on sunscreen products. These claims include but are not limited to the following: "Sunblock," "sweatproof," and "waterproof." These or similar claims will cause the product to be misbranded under section 502 of the FD&C Act.
(h) Labeling of products containing a combination of sunscreen and skin protectant active ingredients. Statements of identity, indications, warnings, and directions for use, respectively, applicable to each ingredient in the product may be combined to eliminate duplicative words or phrases so that the resulting information is clear and understandable. Labeling provisions in § M016.50(e) of OTC Monograph M016 shall not apply to these products.

Part D—Testing Procedures

§ M020.80 Sun Protection Factor (SPF) test procedure

(a) UV source (solar simulator).

(1) Emission spectrum. A single port or multiport solar simulator should be filtered so that it provides a continuous emission spectrum from 290 to 400 nanometers (nm) with a limit of 1,500 Watts per square meter (W/m²) on total irradiance for all wavelengths between 250 and 1,400 nm.

(i) The solar simulator should have the following percentage of erythema-effective radiation in each specified range of wavelengths:

<table>
<thead>
<tr>
<th>Wavelength range (nm)</th>
<th>Percent erythemal contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;290</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>290-300</td>
<td>1.0-8.0</td>
</tr>
<tr>
<td>290-310</td>
<td>49.0-65.0</td>
</tr>
<tr>
<td>290-320</td>
<td>85.0-90.0</td>
</tr>
<tr>
<td>290-330</td>
<td>91.5-95.5</td>
</tr>
<tr>
<td>290-340</td>
<td>94.0-97.0</td>
</tr>
<tr>
<td>290-400</td>
<td>99.9-100.0</td>
</tr>
</tbody>
</table>

1Calculation of erythema action spectrum described in § M020.80(a)(2).

(ii) In addition, UVA II (320-340 nm) irradiance should equal or exceed 20 percent of the total UV (290-400 nm) irradiance. UVA I (340-400 nm) irradiance should equal or exceed 60 percent of the total UV irradiance.

(2) Erythema action spectrum.

(i) Calculate the erythema action spectrum weighting factor \( V_i \) at each wavelength \( \lambda \):

\[
(A) \ V_i (\lambda) = 1.0 \ (250 < \lambda \leq 298 \text{ nm})
\]
\[
(B) \ V_i (\lambda) = 10^{0.094*(298-\lambda)} \ (298 < \lambda \leq 328 \text{ nm})
\]
(C) \( V_i(\lambda) = 10^{0.015(140-\lambda)} \) (328 <\( \lambda \) ≤ 400 nm)

(ii) Calculate the erythema-effective UV dose (E) delivered by a solar simulator as follows:

\[
E = \sum_{\lambda=250}^{\lambda=400} V_i(\lambda) \times I(\lambda) \times t
\]

Where \( V_i(\lambda) \) = erythema action spectrum weighting factor at each wavelength \( \lambda \).

\( I(\lambda) \) = irradiance (Watts per square meter) at each wavelength \( \lambda \).

\( t \) = exposure time (seconds)

Erythema-effective dose (E) is expressed as effective Joules per square meter (J/m\(^2\)-eff).

(iii) The emission spectrum must be determined using a handheld radiometer with a response weighted to match the spectrum in ISO 17166 CIE S 007/E entitled "Erythemal reference action spectrum and standard erythema dose," dated 1999 (First edition, 1999-12-15; corrected and reprinted 2000-11-15), which is incorporated by reference and is available for inspection at FDA. For further information about inspecting incorporated materials, see https://www.fda.gov. Copies may also be available from the publisher/ISO Copyright Office. The solar simulator output should be measured before and after each phototest or, at a minimum, at the beginning and end of each test day. This radiometer should be calibrated using side-by-side comparison with the spectroradiometer (using the weighting factors determined according to § M020.80(a)(2)(i)) at the time of the annual spectroradiometric measurement of the solar simulator as described in § M020.80(a)(4).

(3) Operation. A solar simulator should have no significant time-related fluctuations (within 20 percent) in radiation emissions after an appropriate warm-up time and demonstrate good beam uniformity (within 20 percent) in the exposure plane. The delivered dose to the UV exposure site must be within 10 percent of the expected dose.

(4) Periodic measurement. To ensure that the solar simulator delivers the appropriate spectrum of UV radiation, the emission spectrum of the solar simulator should be measured at least annually with an appropriate and accurately calibrated spectroradiometer system (results should be traceable to the National Institute for Standards and Technology). In addition, the solar simulator must be recalibrated if there is any change in the lamp bulb or the optical filtering components (i.e., filters, mirrors, lenses, collimating devices, or focusing devices). Daily solar simulator radiation intensity
should be monitored with a broadband radiometer with a response weighted to match the
erythema action spectrum in ISO 17166 CIE S 007/E entitled "Erythemal reference
action spectrum and standard erythema dose," which is incorporated by reference in §
M020.80(a)(2)(iii). If a lamp must be replaced due to failure or aging during a phototest,
broadband device readings consistent with those obtained for the original calibrated lamp
will suffice until measurements can be performed with the spectroradiometer at the
earliest possible opportunity.

(b) SPF standard

(1) Preparation. The SPF standard should be a formulation containing 7-percent padimate
O and 3-percent oxybenzone.

### Composition of the Padimate O/oxybenzone SPF Standard

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Percent by weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Part A:</strong></td>
<td></td>
</tr>
<tr>
<td>Lanolin</td>
<td>4.50</td>
</tr>
<tr>
<td>Cocoa butter</td>
<td>2.00</td>
</tr>
<tr>
<td>Glyceryl monostearate</td>
<td>3.00</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>2.00</td>
</tr>
<tr>
<td>Padimate O</td>
<td>7.00</td>
</tr>
<tr>
<td>Oxybenzone</td>
<td>3.00</td>
</tr>
<tr>
<td><strong>Part B:</strong></td>
<td></td>
</tr>
<tr>
<td>Purified water USP</td>
<td>71.60</td>
</tr>
<tr>
<td>Sorbitol solution</td>
<td>5.00</td>
</tr>
<tr>
<td>Triethanolamine, 99 percent</td>
<td>1.00</td>
</tr>
<tr>
<td>Methylparaben</td>
<td>0.30</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Part C:</strong></td>
<td></td>
</tr>
<tr>
<td>Benzyl alcohol</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>Part D:</strong></td>
<td></td>
</tr>
<tr>
<td>Purified water USP</td>
<td>QS ¹</td>
</tr>
</tbody>
</table>

¹ Quantity sufficient to make 100 grams.

Step 1. Add the ingredients of Part A into a suitable stainless steel kettle equipped
with a propeller agitator. Mix at 77 to 82 °C until uniform.

Step 2. Add the water of Part B into a suitable stainless steel kettle equipped with
a propeller agitator and begin mixing at 77 to 82 °C. Add the remaining
ingredients of Part B and mix until uniform.
Step 3. Add the batch of Step 1 to the batch of Step 2 and mix at 77 to 82 °C until smooth and uniform. Slowly cool the batch to 49 to 54 °C.

Step 4. Add the benzyl alcohol of Part C to the batch of Step 3 at 49 to 54 °C. Mix until uniform. Continue to cool batch to 35 to 41 °C.

Step 5. Add sufficient water of Part D to the batch of Step 4 at 35 to 41 °C to obtain 100 grams of SPF standard. Mix until uniform. Cool batch to 27 to 32 °C.

(2) HPLC assay. Use the following high performance liquid chromatography (HPLC) procedure to verify the concentrations of padimate O and oxybenzone in the SPF standard:

(i) Instrumentation.

(A) Equilibrate a suitable liquid chromatograph to the following or equivalent conditions:

<table>
<thead>
<tr>
<th>(1) Column</th>
<th>C-18, 250 millimeters (mm) length, 4.6 mm inner diameter (5 microns)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Mobile Phase</td>
<td>85:15:0.5 methanol: water: acetic acid</td>
</tr>
<tr>
<td>(3) Flow Rate</td>
<td>1.5 milliliters (mL) per minute</td>
</tr>
<tr>
<td>(4) Temperature</td>
<td>Ambient</td>
</tr>
<tr>
<td>(5) Detector</td>
<td>UV spectrophotometer at 308 nanometers</td>
</tr>
<tr>
<td>(6) Attenuation</td>
<td>As needed</td>
</tr>
</tbody>
</table>

(B) Use HPLC grade reagents for mobile phase.

(ii) Preparation of the HPLC reference standard.

(A) Weigh 0.50 gram (g) of oxybenzone USP reference standard into a 250-mL volumetric flask. Dissolve and dilute to volume with isopropanol. Mix well.

(B) Weigh 0.50 g of padimate O USP reference standard into a 250-mL volumetric flask. Dissolve and dilute to volume with isopropanol. Mix well.

(C) Pipet 3.0 mL of the oxybenzone solution and 7.0 mL of the padimate O solution into a 100-mL volumetric flask. Dilute to volume with isopropanol and mix well.

(iii) HPLC system suitability.
(A) Make three replicate 10-microliter injections of the HPLC reference standard (described in § M020.80(b)(2)(ii)). The relative standard deviation in peak areas should not be more than 2.0 percent for either oxybenzone or padimate O.

(B) Calculate the resolution (R) between the oxybenzone and padimate O peaks from one chromatogram as follows:

\[
R = \frac{2 \times (t_o - t_p)}{W_o + W_p}
\]

Where \( t_o \) = retention time for oxybenzone

\( t_p \) = retention time for padimate O

\( W_o \) = oxybenzone peak width at baseline

\( W_p \) = padimate O peak width at baseline

If the resolution (R) is less than 3.0, adjust the mobile phase or replace the column.

(iv) SPF standard assay

(A) The SPF standard is diluted to the same concentration as the HPLC reference standard according to the following steps:

(1) Step 1. Weigh 1.0 g of the SPF standard (described in § M020.80(b)(1)) into a 50-mL volumetric flask.

(2) Step 2. Add approximately 30 mL of isopropanol and heat with swirling until contents are evenly dispersed.

(3) Step 3. Cool to room temperature (15 to 30 °C) and dilute to volume with isopropanol. Mix well.

(4) Step 4. Pipet 5.0 mL of the preparation into a 50-mL volumetric flask and dilute to volume with isopropanol. Mix well.

(B)(1) Inject 10-microliter of diluted SPF standard from paragraph § M020.80(b)(2)(iv)(A) and calculate the amount of oxybenzone and padimate O as follows:

\[
\text{Percent Oxybenzone} = \frac{\text{Peak area of oxybenzone in sunscreen standard}}{\text{Peak area of oxybenzone in HPLC reference standard}} \times 100
\]
Percent Padimate O = \( \frac{\text{Peak area of padimate O in sunscreen standard}}{\text{Peak area of padimate O in HPLC reference standard}} \times 100 \)

(2) The percent of oxybenzone and padimate O in the SPF standard should be between 95 and 105.

(c) Test subjects

(1) Number of subjects. A test panel should include enough subjects to produce a minimum of 10 valid test results. A maximum of three subjects may be rejected from this panel based on § M020.80(e)(5).

(2) Medical history.

(i) Obtain a medical history from each subject with emphasis on the effects of sunlight on the subject's skin. Determine that each subject is in good general health with skin type 1, 2, or 3 as follows:

(1) Always burns easily; never tans (sensitive).

(2) Always burns easily; tans minimally (sensitive).

(3) Burns moderately; tans gradually (light brown) (normal).

(4) Burns minimally; always tans well (moderate brown) (normal).

(5) Rarely burns; tans profusely (dark brown) (insensitive).

(6) Never burns; deeply pigmented (insensitive).

(ii) Skin type is based on first 30 to 45 minutes of sun exposure after a winter season of no sun exposure. Determine that each subject is not taking topical or systemic medication that is known to alter responses to UV radiation. Determine that each subject has no history of sensitivities to topical products and/or abnormal responses to sunlight, such as a phototoxic or photoallergic response.
(3) Physical examination. Conduct a physical examination to determine the presence of sunburn, suntan, scars, active dermal lesions, and uneven skin tones on the areas of the back to be tested. A suitable source of low power UVA, such as a Woods lamp, is helpful in this process. If any of these conditions are present, the subject is not qualified to participate in the study. The presence of nevi, blemishes, or moles will be acceptable if, in the physician's judgment, they will neither compromise the study nor jeopardize a subject's safety. Subjects with dysplastic nevi should not be enrolled. Excess hair on the back is acceptable if the hair is clipped. Shaving is unacceptable because it may remove a significant portion of the stratum corneum and temporarily alter the skin's response to UV radiation.

(4) Informed consent. Obtain legally effective written informed consent from all test subjects.

(d) Sunscreen application.

(1) Test site. Test sites are locations on each subject's back, between the beltline and the shoulder blades (scapulae) and lateral to the midline, where skin responses to UV radiation are determined. Responses on unprotected skin (no test material applied) and protected skin (sunscreen test product(s) or SPF standard applied) are determined at separate unprotected and protected test sites, respectively. Test sites should be randomly located in a blinded manner. Each test site should be a minimum of 30 square centimeters and outlined with indelible ink.

(2) Test subsite. Test subsites are the locations to which UV radiation is administered within a test site. At least five test subsites should receive UV doses within each test site. Test subsites should be at least 0.5 square centimeters (cm²) in area and should be separated from each other by at least 0.8 cm. Each test subsite should be outlined with indelible ink.

(3) Applying test materials. Apply the sunscreen test product and the SPF standard at 2 milligrams per square centimeter (mg/cm²) to their respective test sites. Use a finger cot compatible with the sunscreen to spread the product as evenly as possible.

(4) Waiting period. Wait at least 15 minutes after applying a sunscreen product before exposing the test sites to UV radiation as described in § M020.80(e). For water resistant sunscreen products, proceed with the water resistance testing procedure described in § M020.80(g) after waiting at least 15 minutes.
(e) UV exposure

(1) Definition of minimal erythema dose (MED). The minimal erythema dose (MED) is the smallest UV dose that produces perceptible redness of the skin (erythema) with clearly defined borders at 16 to 24 hours after UV exposure. The MED for unprotected skin (MEDu) is determined on a test site that does not have sunscreen applied. The MED for protected skin (MEDp) is determined on a test site that has sunscreen applied. An MEDp is determined for the SPF standard (ssMEDp). An MEDp is determined for the sunscreen test product (tpMEDp).

(2) UV exposure for initial MEDu. For each test subject, administer a series of UV radiation doses expressed as J/m$^2$-eff (as determined according to § M020.80(a)(2)(ii)) to the test subsites within an unprotected test site using an accurately calibrated solar simulator. Select doses that are a geometric series represented by 1.25$^n$ (i.e., each dose is 25 percent greater than the previous dose).

(3) UV exposure for final MEDu, ssMEDp, and tpMEDp. For each subject, determine the final MEDu, ssMEDp, and tpMEDp by administering a series of five UV doses to the appropriate test sites. The middle dose (X) in each of these dose series (i.e., the third dose) should equal the initial MEDu times the expected SPF. Note that the expected SPF equals 1 and 16.3 for the final MEDu and ssMEDp, respectively. The remaining UV doses in the series depend upon the expected SPF value of the sunscreen test product(s).

For products with an expected SPF less than 8, administer UV doses that increase by 25 percent with each successive dose (i.e., 0.64X, 0.80X, 1.00X, 1.25X, and 1.56X). For products with an expected SPF from 8 to 15, administer UV doses that increase by 20 percent with each successive dose (i.e., 0.69X, 0.83X, 1.00X, 1.20X, and 1.44X). For products with an expected SPF higher than 15, administer UV doses that increase by 15 percent with each successive dose (i.e., 0.76X, 0.87X, 1.00X, 1.15X, and 1.32X).

(4) Evaluation of test subsites. In order that the person who evaluates the test subsites is not biased, he/she should not be the same person who applied the sunscreen drug product to the test site or administered the UV doses. After UV doses are administered, all immediate responses should be recorded. These may include an immediate darkening or tanning, typically grayish or purplish in color, which fades in 30 to 60 minutes; an immediate reddening at the subsite, due to heating of the skin, which fades rapidly; and an immediate generalized heat response, spreading beyond the subsite, which fades in 30 to 60 minutes. After the immediate responses are noted, each subject should shield the exposed area from further UV radiation until the MED is determined. Determine the MED 16 to 24 hours after UV exposure. Because erythema is evaluated 16 to 24 hours after UV exposure, the final MEDu, ssMEDp, and tpMEDp are typically determined the day following determination of the initial MEDu. Evaluate the erythema responses of each test subsite using either tungsten or warm white fluorescent lighting that provides at least 450 lux of illumination at the test site. For the evaluation, the test subject should be in the same position as when the test site was irradiated.
(5) Invalid test data. Reject test data for a test subject if erythema is not present on either the unprotected or protected test sites; or erythema is present at all subsites; or the responses are inconsistent with the series of UV doses administered; or the subject was noncompliant (e.g., the subject withdraws from the test due to illness or work conflicts or does not shield the exposed testing sites from further UV radiation until the MED is determined).

(f) Determination of SPF.

(1) Calculate an SPF value for each test subject (SPFi) as follows:

\[
SPFi = \frac{MEDp}{MEDu}
\]

(2) Calculate the mean

\[
\overline{SPF} = \frac{\sum SPFi}{n}
\]

and the standard deviation (s) from the SPFi values. Calculate the standard error (SE), which equals \( s/\sqrt{n} \) (where \( n \) equals the number of subjects who provided valid test results). Obtain the \( t \) value from Student's t distribution table corresponding to the upper 5-percent point with \( n-1 \) degrees of freedom. Determine the labeled SPF value, which equals the largest whole number less than

\[
\overline{SPF} - (t \times SE).
\]

In order for the SPF determination of a test product to be considered valid, the SPF value of the SPF standard should fall within the standard deviation range of the expected SPF (i.e., 16.3 ± 3.43).

(g) Determination of water resistance.

The following procedure should be performed in an indoor fresh water pool, whirlpool, and/or hot tub maintained at 23 to 32 °C. Fresh water is clean drinking water that meets the standards in 40 CFR part 141. The pool and air temperature and the relative humidity should be recorded.

(1) Water resistance (40 minutes). The labeled SPF should be determined after 40 minutes of water immersion using the following procedure:

(i) Step 1: Apply the sunscreen as described in § M020.80(d).
(ii) Step 2: Perform moderate activity in water for 20 minutes.

(iii) Step 3: Rest out of water for 15 minutes. Do not towel test site(s).

(iv) Step 4: Perform moderate activity in water for 20 minutes.

(v) Step 5: Allow test sites to dry completely without toweling.

(vi) Step 6: Apply the SPF standard as described in § M020.80(d).

(vii) Step 7. Expose test sites to UV doses as described in § M020.80(e).

(2) Water resistance (80 minutes). The labeled SPF should be determined after 80 minutes of water immersion using the following procedure:

(i) Step 1: Apply the sunscreen as described in § M020.80(d).

(ii) Step 2: Perform moderate activity in water for 20 minutes.

(iii) Step 3: Rest out of water for 15 minutes. Do not towel test site(s).

(iv) Step 4: Perform moderate activity in water for 20 minutes.

(v) Step 5: Rest out of water for 15 minutes. Do not towel test site(s).

(vi) Step 6: Perform moderate activity in water for 20 minutes.

(vii) Step 7: Rest out of water for 15 minutes. Do not towel test site(s).

(viii) Step 8: Perform moderate activity in water for 20 minutes.

(ix) Step 9: Allow test sites to dry completely without toweling.

(x) Step 10: Apply the SPF standard as described in § M020.80(d).

(xi) Step 11: Expose test sites to UV doses as described in § M020.80(e).

§ M020.90 Broad spectrum test procedure

(a) UV Spectrometry.

(1) Plate. Use optical-grade polymethylmethacrylate (PMMA) plates suitable for UV transmittance measurements. The plate should be roughened on one side to a three dimensional surface topography measure (Sa) between 2 and 7 micrometers and must have a rectangular application area of at least 16 square centimeters (with no side shorter than 4 cm).
(2) Sample holder. The sample holder should hold the PMMA plate in a horizontal position to avoid flowing of the sunscreen drug product from one edge of the PMMA plate to the other. It should be mounted as close as possible to the input optics of the spectrometer to maximize capture of forward scattered radiation. The sample holder should be a thin, flat plate with a suitable aperture through which UV radiation can pass. The PMMA plate should be placed on the upper surface of the sample holder with the roughened side facing up.

(3) Light source. The light source should produce a continuous spectral distribution of UV radiation from 290 to 400 nanometers.

(4) Input optics. Unless the spectrometer is equipped with an integrating sphere, an ultraviolet radiation diffuser should be placed between the sample and the input optics of the spectrometer. The diffuser will be constructed from any UV radiation transparent material (e.g., Teflon® or quartz). The diffuser ensures that the radiation received by the spectrometer is not collimated. The spectrometer input slits should be set to provide a bandwidth that is less than or equal to 1 nanometer.

(5) Dynamic range of the spectrometer. The dynamic range of the spectrometer should be sufficient to measure transmittance accurately through a highly absorbing sunscreen product at all terrestrial solar UV wavelengths (290 to 400 nm).

(b) Sunscreen product application to PMMA plate. The accuracy of the test depends upon the application of a precisely controlled amount of sunscreen product with a uniform distribution over the PMMA plate. The product is applied at 0.75 mg per square centimeter to the roughened side of the PMMA plate. The sunscreen product should be applied in a series of small dots over the entire PMMA plate and then spread evenly using a gloved finger. Spreading should be done with a very light spreading action for approximately 30 seconds followed by spreading with greater pressure for approximately 30 seconds. The plate should then be allowed to equilibrate for 15 minutes in the dark before the pre-irradiation described in § M020.90(c).

(c) Sunscreen product pre-irradiation. To account for lack of photostability, apply the sunscreen product to the PMMA plate as described in § M020.90(b) and then irradiate with a solar simulator described in § M020.80(a). The irradiation dose should be 4 MEDs which is equivalent to an erythemal effective dose of 800 J/m² (i.e., 800 J/m²-eff).
(d) Calculation of mean transmittance values. After pre-irradiation described in § M020.90(c), mean transmittance values should be determined for each wavelength $\lambda$ over the full UV spectrum (290 to 400 nanometers). The transmittance values should be measured at 1 nanometer intervals. Measurements of spectral irradiance transmitted for each wavelength $\lambda$ through control PMMA plates coated with 15 microliters of glycerin (no sunscreen product) should be obtained from at least 5 different locations on the PMMA plate [$C1(\lambda), C2(\lambda), C3(\lambda), C4(\lambda),$ and $C5(\lambda)$]. In addition, a minimum of 5 measurements of spectral irradiance transmitted for each wavelength $\lambda$ through the PMMA plate covered with the sunscreen product will be similarly obtained after pre-irradiation of the sunscreen product [$P1(\lambda), P2(\lambda), P3(\lambda), P4(\lambda),$ and $P5(\lambda)$].

The mean transmittance for each wavelength,

$$T(\lambda) = \frac{\sum P(\lambda)/n}{\sum C(\lambda)/n}$$

Where $n \geq 5$

(e) Calculation of mean absorbance values.

(1) Mean transmittance values,

$$T(\lambda)$$

are converted into mean absorbance values,

$$A(\lambda)$$

at each wavelength by taking the negative logarithm of the mean transmittance value as follows:

$$A(\lambda) = -\log T(\lambda)$$

(2) The calculation yields 111 monochromatic absorbance values in 1 nanometer increments from 290 to 400 nanometers.

(f) Number of plates. For each sunscreen product, mean absorbance values should be determined from at least three individual PMMA plates. Because § M020.90(d) requires at least 5 measurements per plate, there should be a total of at least 15 measurements.
(g) Calculation of the critical wavelength. The critical wavelength is identified as the wavelength at which the integral of the spectral absorbance curve reaches 90 percent of the integral over the UV spectrum from 290 to 400 nm. The following equation defines the critical wavelength:

\[ \int_{290}^{\lambda_c} A(\lambda) \, d\lambda = 0.9 \int_{290}^{400} A(\lambda) \, d\lambda \]

Where \( \lambda_c \) = critical wavelength

\( A(\lambda) \) = mean absorbance at each wavelength

\( d\lambda \) = wavelength interval between measurements

A mean critical wavelength of 370 nm or greater is classified as broad spectrum protection.